Back to Search
Start Over
Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology.
- Source :
-
NAM perspectives [NAM Perspect] 2023 Nov 15; Vol. 2023. Date of Electronic Publication: 2023 Nov 15 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Competing Interests: Conflict-of-Interest Disclosures: Amy Abernethy reports personal fees from Verily/Alphabet, relationships with Georgiamune and EQRx, and personal investments in Iterative Health and One Health, outside the submitted work. Elliot Chaikof reports grants from the National Institutes of Health, outside the submitted work. George Q. Daley reports holding equity from Redona Therapeutics and from iTCells, outside the submitted work. Juan Enriquez reports investments with Excel Venture Management, outside the submitted work; investments in various life science technologies, including leading-edge brain technologies, and co-authoring a book on the impact of emerging brain technologies. Scott Gottlieb reports personal fees from Pfi zer, Inc, Illumina, Inc, Aetion, Tempus Labs, National Resilience, Inc, Cell-Carta, Parker Institute for Cancer Immunotherapy, Mount Sinai Health System, New Enterprise Associates, and American Enterprise Institute outside the submitted work. Sohail Tavazoie reports personal fees from Inspirna, outside the submitted work. Jacob S. Sherkow reports employment with the University of Illinois, grants from National Institutes of Health, and personal fees from Expert Consulting services, outside the submitted work.
Details
- Language :
- English
- ISSN :
- 2578-6865
- Volume :
- 2023
- Database :
- MEDLINE
- Journal :
- NAM perspectives
- Publication Type :
- Academic Journal
- Accession number :
- 38855738
- Full Text :
- https://doi.org/10.31478/202311d